SNRI Dosing for Anxiety Treatment

Introduction to SNRI Dosing

The American Academy of Child and Adolescent Psychiatry recommends starting duloxetine at 30 mg once daily for one week, then increasing to the target dose of 60 mg once daily, which is effective for most patients and FDA-approved for generalized anxiety disorder 1

For adults under 65 years, the initial dose of duloxetine is 30 mg once daily, and the target dose is 60 mg once daily, with a maximum studied dose of 120 mg once daily, though no evidence supports additional benefit above 60 mg/day 2
For pediatric patients (ages 7-17) with generalized anxiety disorder, duloxetine is the only SNRI with FDA approval, with an initial dose of 30 mg once daily for 2 weeks, and a target range of 30-60 mg once daily 1, 2

The Mayo Clinic recommends an initial dose of 37.5-75 mg once daily for venlafaxine, with a target range of 150-225 mg once daily for anxiety disorders, and a titration time of 2-4 weeks to reach therapeutic dose 3
The American Academy of Child and Adolescent Psychiatry suggests that extended-release venlafaxine is preferred for convenience and tolerability, with once daily dosing due to its longer half-life 1

The American Academy of Child and Adolescent Psychiatry recommends duloxetine as a first-line choice due to its FDA indication for GAD, simpler dosing, and no cardiovascular monitoring below therapeutic doses 1, 2
The Mayo Clinic suggests avoiding venlafaxine in patients with cardiovascular disease, as blood pressure elevation occurs dose-dependently, especially above 225 mg/day 3

The American Academy of Child and Adolescent Psychiatry recommends monitoring blood pressure and pulse at baseline and during treatment for all SNRIs, with particular caution for venlafaxine doses above 150 mg/day 1, 2, 4
The Praxis Medical Insights guideline suggests assessing suicidal ideation at baseline and early treatment, particularly in patients under 24 years, and monitoring height and weight in pediatric patients 1, 4

The Journal of the American Academy of Child and Adolescent Psychiatry recommends tapering venlafaxine slowly due to the highest risk of discontinuation syndrome, and tapering duloxetine over at least 2 weeks to minimize discontinuation symptoms 1, 2
The Praxis Medical Insights guideline suggests gradual tapering of desvenlafaxine to minimize discontinuation symptoms 4

The Praxis Medical Insights guideline states that MAOIs are an absolute contraindication with all SNRIs due to serotonin syndrome risk, with a recommended 14-day washout period when switching between MAOIs and SNRIs 2, 4